The efficiency of anti-activated factor X and anti-activated factor II anticoagulants

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 3, 2007, Pages 265-269

  Stief, Thomas W ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Argatroban; Dalteparin; Danaparoid; Extrinsic coagulation activity assay; Fondaparinux; Heparin; Hirudin; Low molecular weight heparin; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; ARGININE; BLOOD CLOTTING FACTOR 10; BOVINE SERUM ALBUMIN; CALCIUM CHLORIDE; DALTEPARIN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRUDIN; LEPIRUDIN; PROTHROMBIN; SERUM ALBUMIN; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN;

ARTICLE; ASSAY; BLOOD PH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IC 50; NORMAL HUMAN; PRIORITY JOURNAL; REACTION TIME; TEMPERATURE;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG EVALUATION; FACTOR XA; HUMANS; PROTHROMBIN; THERAPEUTIC EQUIVALENCY; THROMBIN;

EID: 34247172615     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32809c2f61     Document Type: Article

References (20)

1. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004; 104:3072-3077.
2. Ieko M, Tarumi T, Nakabayashi T, Yoshida M, Naito S, Koike T. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics. Front Biosci 2006; 11:232-248.
3. Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology 2005; 10:271-275.
4. Severin T, Zieger B, Sutor AH. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost 2002; 28:447-454.
5. Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002; 62:2283-2314.
6. Acostamadiedo JM, Iyer UG, Owen J. Danaparoid sodium. Expert Opin Pharmacother 2000; 1:803-814.
7. Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54:903-924.
8. Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005; 6:1349-1371.
9. Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 2005; 60:565-574.
10. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides. Clin Geriatr Med 2006; 22:1-15.
11. Fareed J, Jeske WP. Small-molecule direct antithrombins: argatroban. Best Pract Res Clin Haematol 2004; 17:127-138.
12. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002; 39:187-196.
13. Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis 2002; 13:41-47.
14. Stief TW. Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation. Clin Appl Thromb Hemost 2006; 12:137-161.
15. Stief TW, Wieczerzak A, Renz H. Influence of coagulation factors on extrinsic thrombin generation. Blood Coagul Fibrinol 2007; 18:105-112.
16. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96:553-561.
17. Stief TW. Specific determination of plasmatic thrombin activity. Clin Appl Thromb Hemost 2006; 12:324-329.
18. - test: the corrected chi-square comparison against the control-mean. Clin Appl Thromb/Hemost 2007; 13:73-100.
19. Okwusidi JI, Anvari N, Ofosu FA. Modulation of intrinsic prothrombin activation by fibrinogen and fibrin I. J Lab Clin Med 1993; 121:64-70.
20. Mosesson MW, Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89:9-12.